8-K current report · filed Oct 15, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: October 15, 2026

Item 7.01AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA accepted Anaphylm NDA resubmission as complete, advancing the product into formal regulatory review.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA accepted Anaphylm NDA resubmission as complete, advancing the product into formal regulatory review
  • PDUFA goal date set for March 16, 2027, creating a defined approval catalyst
  • Anaphylm targets Type I allergic reactions, including anaphylaxis, expanding Aquestive’s commercial opportunity upon approval

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.